Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...

Allison covered what hot startups are getting up to, and who’s financing them. She was also co-host of the weekly biotech podcast, “The Readout Loud.” Recursion Pharmaceuticals announced results of a ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...